Kitazato (368A) FY2027 Q1 Earnings Report

Quick View

Executive Summary

In FY2027 Q1, the Medical Equipment Business posted increases in both revenue and profit while maintaining high profitability. Revenue was ¥30.2B (¥24.3B in the previous year, YoY +24.0%), Operating Income was ¥15.2B (up +27.0%), Ordinary Income was ¥15.3B (up +36.5%), and Net Income attributable to owners of the parent was ¥10.1B (up +35.2%). The growth rate of Operating Income exceeded revenue growth, indicating operating leverage supported by the continued low SG&A ratio of 12.2%. The ¥0.2B difference between Ordinary Income and Operating Income was attributable to non-operating income, including foreign exchange gains; the primary drivers of profit growth were higher revenue and improved margins in the core business.

Factors Affecting Business Performance

【Revenue】Revenue was ¥30.2B, representing a substantial increase of +24.0% year on year. The Group operates as a single segment, the Medical Equipment Business, and expanding demand in this business directly contributed to the increase in revenue. Progress against the full-year revenue forecast of ¥113.5B (up +3.6% year on year) was 26.6%, exceeding the standard 25%.

【Profit and Loss】Operating Income was ¥15.2B (YoY +27.0%), with a gross profit margin of 62.5% and an SG&A ratio of 12.2%, indicating a favorable earnings structure. The Operating Income margin was 50.3%, improving by approximately 1.2pt year on year. Ordinary Income was ¥15.3B (YoY +36.5%); a foreign exchange gain of ¥0.1B boosted non-operating income, but its scale was small and did not materially distort the assessment of core business profitability. Net Income was ¥10.1B (YoY +35.2%), with an effective tax rate of 34.4%. Accordingly, the current period can be characterized as one of higher revenue and higher profit.

Segment Analysis

The Group operates as a single segment, the Medical Equipment Business, and disclosure of segment-level details has been omitted.

Key Financial Indicators

【Profitability】The Operating Income margin of 50.3% and Net Income margin of 33.4% both improved from the same period of the previous year (approximately 49.1% for the Operating Income margin and approximately 30.6% for the Net Income margin). The gross profit margin remained high at 62.5%.【Cash Flow Quality】Annualized inventory turnover days were 162 days, while the annualized cash conversion cycle (CCC) was 184 days; both have lengthened. Accounts payable of ¥2.1B compared with accounts receivable of ¥13.0B indicates that the offsetting effect of trade payables on working capital is limited.【Investment Efficiency】Annualized ROE was 5.1%, decomposed into a Net Income margin of 33.4% × total asset turnover of 0.144x × financial leverage of 1.06x. Revenue turnover is low relative to the asset base, which is centered on cash and cash equivalents of ¥125.1B, constraining capital efficiency.【Financial Soundness】With an Equity Ratio of 94.6%, a current ratio of 1,499.7%, and a debt-to-equity ratio of 0.06x, financial safety remains at an exceptionally high level.

Cash Flow Analysis

Although a cash flow statement has not been disclosed, funding trends can be assessed from changes in the balance sheet. Cash and deposits were ¥125.1B, down from ¥134.1B in the previous year, while their ratio to total assets of ¥209.9B remained high at 59.6%. Accounts receivable declined to ¥13.0B (¥15.6B in the previous year), while inventories decreased to ¥3.5B (¥4.0B in the previous year), indicating a trend toward working capital reduction. Nevertheless, annualized inventory turnover days of 162 days and a CCC of 184 days are lengthy, suggesting that cash tied up primarily in inventories may be restricting the conversion of profit into cash. Property, plant and equipment stood at ¥46.0B, representing only a slight year-on-year increase, indicating that large-scale capital investment was limited. The financial structure of substantial cash and low debt provides considerable funding flexibility.

Earnings Quality

The primary drivers of profit growth in the current period were higher revenue from the core business and an improved Operating Income margin, and earnings quality can be considered generally favorable. Of the ¥0.2B in non-operating income, the foreign exchange gain was ¥0.1B and interest income was slightly less than ¥0.1B; the extent to which Ordinary Income exceeded Operating Income was small at ¥0.2B. No extraordinary gains or losses were recorded, and no profit enhancement from temporary factors was identified. The effective tax rate was 34.4%, with the tax burden somewhat suppressing the increase in the Net Income margin. Comprehensive income was ¥10.1B, broadly in line with Net Income of ¥10.1B, with no material divergence from Net Income attributable to valuation differences on other securities or similar items. Accordingly, current-period profit can be assessed as being close to the underlying earning power of the core business.

Earnings Forecast and Guidance

Q1 progress against the full-year company forecast was 26.6% for revenue, 24.8% for Operating Income, 25.0% for Ordinary Income, and 24.8% for Net Income. While revenue progress exceeded the standard 25%, profit progress remained generally in line with the standard level. The Q1 Operating Income margin of 50.3% was approximately 3.6pt below the full-year forecast Operating Income margin of 53.9%, requiring an improvement in profitability from Q2 onward to achieve the full-year plan. No revisions were made to the earnings forecast or dividend forecast during the quarter.

Shareholder Returns

The full-year dividend forecast is ¥41.00 per share, with no revisions made during the period. Assuming 40 million shares outstanding, the annual dividend total is estimated at approximately ¥1.64B. The Payout Ratio relative to the full-year forecast of ¥4.06B in Net Income attributable to owners of the parent is approximately 40.4%, calculated on a consistent basis. Given the financial capacity represented by retained earnings of ¥19.86B and cash and cash equivalents of ¥125.1B, the sustainability of this dividend level is considered high. There is no disclosure regarding share repurchases.

Risk Factors

1. Inventory accumulation risk: Annualized inventory turnover days were 162 days, substantially exceeding the generally cautious threshold of 90 days. Since changes in product life cycles and regulatory requirements may affect the value of medical equipment inventories, attention will be focused on sales progress and trends in inventory composition (raw materials ¥1.07B, work in process ¥0.59B, finished goods ¥0.35B).

2. Working capital efficiency risk: The annualized cash conversion cycle was 184 days, exceeding the generally cautious threshold of 120 days. Although cash and cash equivalents are substantial, continued lengthening of the working capital cycle could affect capital efficiency.

3. Single-segment concentration risk: The Group consists of a single segment, the Medical Equipment Business, creating a structure in which fluctuations in demand in that market directly affect business performance.

Industry Benchmark (Reference; Compiled by the Company)

Industry Benchmark (manufacturing)

Profitability and Returns

Both the Operating Income margin and Net Income margin were substantially above the industry median, indicating exceptional profitability within the industry.

Growth and Capital Efficiency

The revenue growth rate also substantially exceeded the industry median, indicating an advantage in both profitability and growth.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. Revenue increased +24.0%, Operating Income increased +27.0%, and Net Income increased +35.2%. In addition to higher revenue and profit, margins improved from the same period of the previous year, resulting in earnings driven by operating leverage.

2. While financial safety was exceptionally high, with an Equity Ratio of 94.6%, a current ratio of 1,499.7%, and a debt-to-equity ratio of 0.06x, annualized ROE remained at 5.1%. The low asset turnover resulting from substantial cash and cash equivalents is a defining feature of capital efficiency.

3. Annualized inventory turnover days of 162 days and a cash conversion cycle of 184 days indicate that working capital efficiency is relatively low compared with earning power, making future inventory trends a key area of attention.

Theoretical Share Price (Reference Value)

Sensitivity: ¥664–¥703 at ±1% for the cost of equity, and ¥679–¥690 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• Since net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated using only publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own responsibility, after consulting with a professional as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 was a strong start, with revenue, operating profit and net income all growing faster than the full-year plan implies. Revenue increased 24.0% year on year to ¥3.02bn. Operating income rose 27.0% to ¥1.52bn. Net income attributable to owners increased 35.1% to ¥1.01bn. The operating margin expanded by 120bp year on year to 50.3%, from 49.1% in the prior-year quarter. The net margin expanded by 280bp to 33.4%, from 30.6%. Gross margin was 62.5%, demonstrating exceptionally high value added for a medical-device manufacturer. SG&A expense declined 1.3% year on year to ¥0.37bn while revenue grew 24.0%, producing substantial positive operating leverage. Ordinary income grew 36.5%, faster than operating income, aided by ¥0.13bn of foreign-exchange gains and ¥0.05bn of interest income. The effective tax rate was 34.4%, resulting in a tax burden factor of 0.656. Annualized ROE was 20.3%, an excellent level, supported mainly by profitability rather than leverage. Annualized ROA was approximately 18.7%, calculated using annualized Q1 net income and average total assets, also indicating very strong capital efficiency. The balance sheet remains exceptionally conservative, with ¥12.51bn of cash and deposits, a 94.6% equity ratio and only ¥1.12bn of liabilities. Liquidity is abundant, with a current ratio of 15.0x and quick ratio of 14.7x. The principal operating issue is working-capital efficiency: the quality alerts indicate inventory days of 162 days and a cash-conversion cycle of 184 days. Q1 revenue represents 26.6% of the full-year forecast and operating income represents 24.8%, broadly in line with normal 25% first-quarter seasonality. Management has maintained its full-year forecasts, which call for only 3.6% revenue growth and 4.4% operating-income growth, leaving meaningful scope for performance to normalize after a strong first quarter or for potential upside if momentum persists.

Profitability Analysis

The annualized DuPont ROE of 20.3% decomposes into a 33.4% net profit margin, 0.575x annualized asset turnover and 1.06x financial leverage. Profitability is the dominant ROE driver, while leverage makes only a minimal contribution. The 33.4% net margin improved 280bp year on year, principally reflecting a 120bp increase in operating margin and a favorable shift in non-operating income. Gross profit increased 20.3% to ¥1.89bn and the gross margin remained very high at 62.5%. Operating income increased faster than sales because SG&A fell to ¥0.37bn from ¥0.37bn in the prior year despite the strong revenue expansion. This expense discipline drove operating leverage, although the sustainability of a year-on-year SG&A decline should be monitored as the company invests to support growth. Ordinary income exceeded operating income by ¥0.18bn, equivalent to 0.6% of revenue, including foreign-exchange gains of ¥0.13bn and interest income of ¥0.05bn. Therefore, the bulk of earnings remains operating in nature rather than dependent on non-operating items. The interest burden factor of 1.012 confirms that non-operating income modestly enhanced pre-tax profit, while the absence of interest expense reflects the net-cash financial structure. The tax burden factor of 0.656 and effective tax rate of 34.4% are the main deductions between pre-tax and net income. Asset turnover of 0.575x is solid given the large cash balance, but it is lower in importance than margins in explaining returns. Financial leverage of only 1.06x indicates that the high ROE is achieved without material balance-sheet risk.

Growth Assessment

Revenue growth of 24.0% materially exceeded the 3.6% full-year revenue-growth assumption embedded in guidance. Operating-profit growth of 27.0% also exceeded the 4.4% full-year planned rate, with margin expansion demonstrating favorable operating leverage. Q1 revenue progress was 26.6% against the ¥11.35bn full-year forecast, 1.6 percentage points above the standard 25% Q1 pace. Operating-income progress was 24.8% against the ¥6.12bn forecast, essentially in line with the standard pace. Ordinary-income progress was 25.0% against the ¥6.14bn forecast. Net-income progress was 24.8% against the ¥4.06bn forecast. The quarterly result therefore supports the stated full-year plan, but does not by itself establish a material forecast beat because earnings progress is close to normal seasonality. The company operates in a single medical-device business segment, making group growth closely tied to demand conditions, product competitiveness and execution within that core business. The 62.5% gross margin and 50.3% operating margin provide a substantial earnings buffer. However, the high inventory-days and cash-conversion-cycle alerts indicate that growth should be assessed alongside inventory normalization and cash realization. Management has not revised either earnings or dividend guidance.

Financial Health

Financial health is exceptionally strong. Total equity was ¥19.87bn, equivalent to 94.6% of total assets, while total liabilities were only ¥1.12bn. The debt-to-equity ratio was 0.06x, far below the 2.0x level associated with aggressive financing. Current assets of ¥16.12bn exceeded current liabilities of ¥1.08bn by ¥15.05bn. The current ratio was 15.0x and the quick ratio was 14.7x, indicating no near-term liquidity stress or maturity mismatch. Cash and deposits of ¥12.51bn represented 59.6% of total assets and exceeded total liabilities by more than eleven times. Accounts receivable were ¥1.30bn, or 6.2% of total assets, while accounts payable were ¥0.21bn. Noncurrent liabilities were limited to ¥0.05bn. The capital structure is therefore highly resilient to demand volatility, foreign-exchange movements or investment requirements. Total assets declined by ¥1.00bn year on year, principally alongside a ¥0.90bn decrease in cash and deposits, while equity declined by ¥0.63bn. PPE of ¥4.60bn represented 21.9% of total assets, demonstrating a meaningful but manageable fixed-asset base for manufacturing operations. Intangible assets were only ¥0.05bn, or 0.2% of assets, limiting intangible-asset and goodwill-related impairment exposure.

Notable B/S Changes

Cash and deposits: -¥0.90bn (-6.7%) year on year to ¥12.51bn - main contributor to the ¥1.00bn decline in total assets, though liquidity remains exceptionally strong. Total equity: -¥0.63bn (-3.1%) year on year to ¥19.87bn - capital adequacy nevertheless improved to 94.6% from 93.2% as liabilities declined more sharply. Total liabilities: -¥0.37bn (-24.7%) year on year to ¥1.12bn - reinforces the already conservative balance sheet and low refinancing risk. Accounts receivable: -¥0.26bn (-16.5%) year on year to ¥1.30bn - directionally supportive for collection discipline and working-capital control. Finished goods: -¥0.50bn (-12.5%) year on year to ¥0.35bn - a favorable year-on-year movement, although the inventory-days alert indicates that overall inventory velocity remains an operating focus. Machinery: +¥0.60bn (+23.0%) year on year to ¥0.32bn - indicates an increase in production-equipment investment within a PPE base of ¥4.60bn.

Cash Flow Quality

The earnings profile is operationally strong, with operating income of ¥1.52bn accounting for the vast majority of pre-tax income of ¥1.54bn. Non-operating income was limited to ¥0.18bn, or 0.6% of revenue, so reported earnings are not materially dependent on below-the-line gains. Foreign-exchange gains contributed ¥0.13bn, equal to 8.6% of operating income, and should be treated as less recurring than core operating profit. Working-capital quality requires attention. The HIGH_INVENTORY_DAYS alert, at 162 days versus the 90-day warning threshold, indicates that capital is tied up in inventory for an extended period. In a medical-device manufacturer, this may reflect long production and regulatory-release cycles, product availability requirements or slower stock rotation; regardless of cause, prolonged inventory holding increases obsolescence, write-down and demand-forecast risk. The LONG_CCC alert, at 184 days versus the 120-day warning threshold, indicates a long interval between cash outlay and customer cash collection. This reduces cash efficiency even though the company has ample liquidity. Accounts receivable declined ¥0.26bn year on year and finished-goods inventory declined ¥0.50bn, which are directionally constructive for balance-sheet working capital. The current cash reserve of ¥12.51bn provides a substantial buffer while management works to improve the operating cash cycle.

Dividend Sustainability

The full-year dividend forecast is ¥41.00 per share, compared with forecast EPS of ¥101.50. This implies a dividend payout ratio of approximately 40.4%, within the sub-60% range generally associated with sustainable dividend distributions. The forecast dividend requires approximately ¥1.64bn based on 40.0 million shares outstanding. Forecast net income of ¥4.06bn covers the planned dividend by about 2.5 times. The company also has retained earnings of ¥198.61bn and cash and deposits of ¥12.51bn, providing substantial balance-sheet support for the distribution. No dividend revision has been announced. The conservative payout ratio leaves financial flexibility for working-capital needs, manufacturing investment and potential shareholder returns. Sustained dividend growth will depend principally on the durability of high operating margins and improvement in the lengthy cash-conversion cycle.

Risk Assessment

Business risks include Working-capital risk: inventory days of 162 exceed the 90-day warning level. In medical devices, extended holding periods can increase the risk of inventory obsolescence, product-mix misalignment, expiry-related losses and production-planning inefficiency., Cash-cycle risk: the 184-day cash-conversion cycle exceeds the 120-day warning level, increasing the amount of capital committed to operations and reducing the speed with which accounting profits convert into available cash., Demand and product-concentration risk: the group reports a single medical-device segment, concentrating earnings exposure in one business domain and increasing sensitivity to product competitiveness, hospital/customer purchasing patterns and regulatory conditions., Foreign-exchange risk: Q1 included ¥0.13bn of foreign-exchange gains, equal to 8.6% of operating income. A reversal in exchange-rate conditions could reduce ordinary-income growth relative to operating-income growth., Margin-normalization risk: the 50.3% operating margin benefited from revenue growth of 24.0% alongside a 1.3% decline in SG&A. If sales growth moderates toward the 3.6% full-year assumption or investment spending rises, incremental margins may normalize..

Financial risks include The balance sheet itself presents low leverage risk, with a 0.06x debt-to-equity ratio, 94.6% equity ratio and current ratio of 15.0x., The key financial risk is capital efficiency rather than solvency: large cash holdings and long working-capital duration may depress returns if not productively deployed., The effective tax rate of 34.4% remains a meaningful drag on conversion of pre-tax profit into net profit..

Key concerns include Highest priority: inventory-day and cash-conversion-cycle alerts, because persistent working-capital intensity can impair cash generation and elevate inventory valuation risk., Medium priority: sustainability of exceptionally high margins and unusually favorable SG&A operating leverage as growth normalizes., Medium priority: the degree to which foreign-exchange gains recur, given their contribution to the outperformance of ordinary-income growth over operating-income growth., Lower priority: liquidity and refinancing risk, which are limited by the substantial net-cash position and minimal liabilities..

Investment Implications

Key takeaways include Q1 revenue, operating income and net income grew 24.0%, 27.0% and 35.1% year on year, respectively., Operating margin improved to 50.3% and net margin to 33.4%, placing profitability well above standard manufacturing benchmarks., Annualized ROE of 20.3% is driven by operating profitability rather than financial leverage., Q1 revenue progress of 26.6% and operating-profit progress of 24.8% are broadly consistent with the full-year plan., The balance sheet is exceptionally conservative, with ¥12.51bn cash, a 94.6% equity ratio and 0.06x debt-to-equity., Working-capital efficiency is the principal operational issue, with 162 inventory days and a 184-day cash-conversion cycle..

Metrics to watch include Revenue growth versus the 3.6% full-year forecast growth rate, Operating margin and SG&A-to-revenue ratio, Inventory days, inventory write-downs and stock rotation, Cash-conversion-cycle improvement, Foreign-exchange gains or losses relative to operating income, Dividend payout ratio versus the approximately 40.4% forecast level, Cash and deposits relative to working-capital and capital-investment requirements.

Regarding relative positioning, The company exhibits unusually high profitability for a manufacturer, with a 62.5% gross margin, 50.3% operating margin and annualized 20.3% ROE, while maintaining a far more conservative capital structure than a leveraged industrial peer. Its relative weakness is working-capital efficiency: the flagged 162-day inventory cycle and 184-day cash-conversion cycle are materially above standard manufacturing benchmarks and require monitoring alongside the strong reported earnings.